trending Market Intelligence /marketintelligence/en/news-insights/trending/iKeBhvvI2hKbjgiKkfJIlg2 content esgSubNav
In This List

US FDA approves Novartis drug as first-line cancer treatment

Blog

Japan M&A By the Numbers: Q4 2023

Blog

Essential IR Insights Newsletter Fall - 2023

Case Study

A Corporation Clearly Pinpoints Activist Investor Activity

Blog

Insight Weekly: Bank mergers of equals return; energy tops S&P 500; green bond sales to rise


US FDA approves Novartis drug as first-line cancer treatment

The U.S. Food and Drug Administration approved Novartis AG's Zykadia as a first-line treatment for patients with a specific type of lung cancer.

The drug was already approved for anaplastic lymphoma kinase-positive, metastatic non-small cell lung cancer patients that failed treatment with Pfizer Inc.'s Xalkori.

The U.S. FDA expanded the use of Zykadia based on the results of a phase 3 trial in patients who received no prior treatment. The study showed a median progression-free survival rate of 16.6 months as opposed to the 8.1 months achieved by those on standard, first-line pemetrexed-platinum chemotherapy with pemetrexed maintenance.